pSivida Corp. (PSDV) Receives FDA Clearance for Application to Treat Posterior Uveitis
The US Food and Drug Administration (FDA) has cleared pSivida’s Investigational New Drug (IND) application to treat posterior uveitis with injectable sustained-release micro-insert. pSivida can now move to Phase III trials, which will be in addition to the investigator-sponsored trial studying the same device for posterior uveitis announced last month. pSivida expects to have 300 participants enroll in the Phase III trials for the injectable sustained-release micro-insert. In the U.S. posterior uveitis affects approximately 175,000 people and is responsible for approximately 30,000 cases of blindness, making it the third largest cause of blindness. It is an ocular inflammatory disease that…